Growth of the Indonesian pharmaceutical market will be supported by the government's quest for better health care provision, according to the latest Business Monitor report on the country’s pharmaceuticals and health care sector.
The Indonesia Pharmaceuticals and Healthcare Report expects that growth will be supported by the industry's desire to capitalise on the government’s health care initiatives. However, it predicts that higher inflation will have a knock-on effect on pharmaceutical prices, which are already prohibitively high for large sections of the population, especially as most patients have to pay their own medical bills in full.
Key developments in 2013
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze